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Summary Since L-dopa (L-3,4-dihydroxyphenylalanine) has been shown to possess a selective toxicity for
melanoma cells both in vitro and in vivo, we have examined the combined effect of L-dopa and radiation on
human melanoma cells. It was found that the combined use of L-dopa potentiated the radiation cytotoxicity to
HMV-I human melanoma cells, compared with the response seen in non-melanoma HeLa S3 cells. In HMV-I
cells during their exponential phase, L-dopa decreased the shoulder width of the radiation survival curve
significantly. In addition, L-dopa significantly inhibited the repair of potentially lethal damage (PLD) in
HMV-I cells during their plateau phase. When the distributions of the G,, S, and G2-M cells were measured
24 h after combined L-dopa and radiation treatment, there was significant increase in the accumulation of cells
in the G2-M phase of the cell cycle, compared to cells that received either L-dopa or radiation treatment only.
L-Dopa (L-3,4-dihydroxyphenlalanine) has been shown to be
selectively toxic to melanoma cells in vitro (Wick et al., 1977).
Further, it has been reported that L-dopa and its chemical
analogues inhibit the growth ofmurine melanoma in vivo and
prolong the survival span of melanoma-bearing mice (Wick,
1978). The mechanism of such action has been postulated to
involve a tyrosinase-mediated oxidation of L-dopa to a
quinone with subsequent sulphydryl group scavenging and
inhibition of enzymes central to DNA synthesis (Graham et
al., 1978; Wick, 1980). Unfortunately, while the clinical inves-
tigation of the effect of L-dopa on advanced human malig-
nant melanomas has already started (Wick, 1983), no study
has yet appeared dealing with the effect of L-dopa when
combined with other therapeutic modalities in the manage-
ment of melanomas. Thus, in this report, we have examined
the effect of L-dopa on the potentiation of radiation damage
to human melanoma cells. We also have evaluated the redis-
tribution of cells in different phases of the cell cycle as a
possible mechanism for the interaction between L-dopa and
radiation.
Materials and methods
Cells
We used the HMV-I human melanoma cell line that was
established from a black-brown malignant melanoma in the
vaginal wall of a woman (Yamada et al., 1987). HeLa S3
cells were used as the non-melanoma control cells. The two
cell lines were maintained in Ham's F-10 medium, supple-
mented with 10% calf serum (Flow Laboratories), penicillin
(100 U ml-'), and streptomycin (100 fig ml-'), and incubated
in a humidified atmosphere of 95% air/5% CO2 at 37°C.
Chemicals
L-Dopa was purchased from Sigma Chemical Co. (St Louis,
MO, USA). The drug solution was freshly prepared in Ham's
F-10 medium just before use at the beginning of each experi-
ment.
Irradiation
Cells that were grown in plastic Petri dishes were irradiated
at room temperature, using a '"Co '-ray unit at a dose rate of
1.44 Gy min-'. For radiation survival studies, the cells were
irradiated with doses of 1, 2, 4, 6, 8 and 10 Gy.
Effects ofL-dopa on radiosensitivity
Two x 105 cells were inoculated into 60-mm Petri dishes and
incubated for 48 hours. One hundred Ag of L-dopa per
millilitre was added to the culture medium immediately
before irradiation. The cells were then irradiated with graded
doses and incubated for 4 h at 37°C.
Effects ofL-dopa on potentially lethal damage (PLD) repair
For PLD repair studies, 2 x 105 cells were inoculated into
60-mm Petri dishes and grown to confluence. During this
period, the medium was changed on alternate days. Cells in
the confluent state were irradiated with graded doses and
incubated for 6 h at 37'C. To examine the effect of L-dopa
on the PLD repair, 100 fig of L-dopa per millilitre was added
to the culture medium immediately before irradiation and
similarly incubated for 6 h.
Colonyformation
After irradiation and L-dopa exposure, the cells of each
treated group were washed and trypsinised, and an appropri-
ate number of cells were plated in duplicate 60 mm Petri
dishes containing 5 ml of the complete medium. The dishes
were incubated at 37°C in an atmosphere of 95% air/5%
CO2 for 14 days. The resulting colonies that contained more
than 50 cells were counted and the survival fraction of each
group was calculated in reference to the untreated control
group. At least three replicate experiments were conducted
for each treatment. The respective survival curves then were
constructed by plotting the surviving fraction as a function of
radiation dose. The slope of the linear portion of the survival
curves was fitted by a least-squares linear regression analysis
and the Do, Dq and n values were calculated. Further, a
linear quadratic analysis was carried out for these survival
curves, and a and values were calculated.
Cell cycle analysis
Cell cycle distributions of melanoma cells treated with L-
dopa and radiation were determined from DNA histograms
measured by flow cytometry. Exponentially growing cells
were exposed to 10Gy radiation and then incubated with
100 pg ml-' L-dopa for four hours. The L-dopa was then
removed by changing the medium. Twenty-four hours later,
the cells were trypsinised from the dish. The cell suspension
was washed twice with a phosphate buffered saline (PBS,
pH 7.2), after which the cells (1 x 106) in 1 ml of PBS were
mixed with 3 ml of cold 95% ethanol, and incubated at
- 20C for 60 min for fixation. The cells then were washed
twice with PBS and incubated in a solution of 1 mg ml' of
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ribonuclease (RNase A, 4396 U mg-', Worthington Bio-
chemical Corp., Freehold, NJ, USA) in PBS for 30 min at
room temperature. After enzyme treatment, the sample was
mixed with 1 ml of 50 g ml-' of propidium iodide (Cal-
biochem, San Diego, CA, USA) in PBS and kept at room
temperature for 60 min for a DNA assay (Dean et al., 1982).
The DNA content per cell was assayed by flow cytometry,
using a FACScan (Becton-Dickinson, Sunnyvale, CA, USA),
with collection of fluorescence emissions having wavelengths
longer than 590 nm. Some I05 cells were analysed and the
distribution histograms of the fluorescence intensity in linear
scale were obtained. Cell cycle analysis by DNA distribution
was performed by using the 'CCANA 1' program reported
by Dean (1980), and the proportions in the G,, S and G2-M
phases were calculated. Each data point represents the mean
of three experiments. The same experiment and analysis were
carried out for the untreated controls, the L-dopa only, and
the radiation only groups.
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Results
Killing effects ofL-dopa
In order to examine the killing effects of L-dopa alone,
exponentially growing cells were exposed to 100 Lg ml-' of
L-dopa for 0-6 hours and survival fractions were determined
using a colony-forming assay. The plating efficiency of the
untreated HMV-I cells was 78 ± 8%, and that of the HeLa
S3 cells, 60 ± 7%. There was no significant reduction in the
survival fraction in cells treated with L-dopa.
Next, HMV-I cells in the confluent state were exposed to
I00 Lg ml' of L-dopa for 0-6 hours. The plating efficiency
of the untreated HMV-I cells in the confluent state was
76 ± 3%, and there was no significant reduction in the sur-
vival fraction in cells treated with L-dopa.
Radiation sensitivities
The radiation dose-response curve of the HMV-I and HeLa
S3 cells are shown in Figure 1. Using a least-squares regres-
sion analysis to fit the survival curve, HMV-I cells had a Do
of 1.49 ± 0.21 Gy, a Dq of 2.92 ± 0.23 Gy, and an n of
7.0 ± 1.33. Thus, the survival curve of the HMV-I cells had a
broader shoulder region than that of the HeLa S3 cells which
showed a Do of 1.41 ± 0.13 Gy, a Dq of 1.89 ±0.18 Gy, and
an n of 3.8 ± 1.20.
When the HMV-I cells were irradiated and then exposed to
100lig ml-' of L-dopa for 4 h, there was significant reduction
in the cell survival in each of the radiation doses examined,
compared with the untreated cells (P <0.05) (Figure 1).
Further, L-dopa decreased the shoulder width of the survival
curve considerably, as indicated by the values of a Do of
1.42±0.11 Gy, a Dq of 0.61 ±0.24Gy, and an n of
1.5 ± 1.12 (Table I). However, the same treatment with L-
dopa did not significantly affect the radiation sensitivity of
the HeLa S3 cells, i.e. a Do of 1.41 Gy ± 0.18, a Dq of
1.90 ± 0.20 Gy, and an n of 4.0 ± 1.63.
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Figure 1 Survival curves of HMV-l and HeLa S3 cells after
irradiation with or without L-dopa treatment. Two x 105 cells
were inoculated into 60-mm Falcon Petri dishes and incubated
for 48 h. Cells were irradiated with graded doses and then
exposed to 100figml-' of L-dopa for 4 h at 37'C. Values repre-
sent a mean of three to five experiments; bars, s.e. *, HMV-I
after radiation alone; 0, HeLa S3 after radiation alone; *,
HMV-I after radiation and L-dopa; 0, HeLa S3 after radiation
and L-dopa.
Table I Radiobiological parameters of HMV-I human melanoma
cells in the exponential state treated with L-dopa
Treatments Do (Gy) n a (Gy'1) p (Gy-2)
Radiation 1.49 ± 0.21 7.0 ± 1.33 0.070 ± 0.007 0.041 ± 0.009
Radiation 1.42 0.11 1.5 ± 1.12 0.514 ± 0.012 0.011 ± 0.004
+ L-dopa
accumulation of G2-M cells was noted in the irradiated cells.
When L-dopa was combined with radiation, an additional
increase in G2-M cells was found. The percentages of cells in
the G,, S, and G2-M phases after different treatments are
listed in Table III.
Discussion
PLD repair
Figure 2 shows the survival curves of the HMV-I cells in the
confluent state. When the HMV-I cells in the confluent state
were incubated for 6 h after irradiation before replating, the
repair of PLD was prominent; the ratio of the Do values
before and after incubation being 1.7 (Table II). However,
when L-dopa was added to the cell cultures immediately
before irradiation and remained for 6 h before replating,
PLD repair was significantly inhibited (P <0.01).
Inhibition ofcell cycleprogression
The DNA histograms shown in Figure 3 indicate that L-dopa
alone did not produce significant changes in the cell cycle
distribution compared to the untreated controls. An
Melanoma cells possess a unique metabolic pathway for the
conversion of L-dopa to melanin that is said to be mediated
by tyrosinase (Pawelek, 1976). Further, it has been shown
that L-dopa is selectively incorporated by melanoma cells and
that it exhibits a selective cytotoxicity (Wick et al., 1977).
Our present study has indicated that L-dopa potentiated
radiation cytotoxicity towards human melanoma cells. The
survival curve of exponentially growing HMV-I melanoma
cells was modified by L-dopa treatment, and a decrease in the
shoulder portion was especially prominent. Many investi-
gators have demonstrated that the large shoulder in the
survival curve of melanoma cells may be related to the poor
radiation response that has been clinically observed in human
melanomas (Barranco et al., 1971; Fertil & Malaise, 1981).
Furthermore, Sasaki (1987) has demonstrated that tumourL-DOPA AND RADIATION ON MELANOMA CELLS 35
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Figure 2 PLD repair in HMV-1
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Table II Radiobiological parameters
cells in the confluent state
Treatments Do (Gy) Do ratio
Radiation 1.17 ± 0.23 1.0
(Oh)
Radiation 1.97 ± 0.11 1.7
(6 h)
Radiation 1.33 ± 0.21 1.1
+L-dopa
(6 h)
cells showing a larger shoulder h
fraction (up to 109-fold) follow
radiotherapy (2 Gy per fractioi
pared with tumour cells showir
the combined use of L-dopa m
overcoming the large shoulder oz
0 c d
a) 100
a) ll
50
I
0 100 200 0 100 200
Fluorescence intensity
Figure 3 DNA histograms of HMV-1 cells after treatment with
L-dopa and 10 Gy radiation. All measurements were made at 24 h
after treatments. a, Untreated control; b, L-dopa only, c, radia-
tion only; d, radiation and L-dopa.
E Z l cells. However, Weichselbaum and 'Little (1982a,b) have de-
6 8 10 12 monstrated that, the larger the fraction dose, the more prom-
se (Gy) inent the repair of the PLD in the melanoma cells, and they
have suggested that the greater repair of PLD may be
cells and its inhibition by L- another important factor determining the poor radiation re-
lated into 60 mm Petri disheS sponse in melanomas. In the management of melanomas,
re irradiated with graded doses therefore, L-dopa may also be an effective agent for
r immediately after irradiation inhibiting the PLD repair.
'LD repair (0), the cells were In addition, the enhancement of cell killing was found to
60-mdsefoanasyo'* 60-mm dishes for an assay of be associated with increased blockage of the HMV-I cells by
100fgfml- of L-dopa for6Ph L-dopa in the G2-M phase. Our data indicated that L-dopa
*esent a mean of three to five exerted a similar degree of inhibition in cell cycle progression
at different phases of the cell cycle, and that the HMV-I cells
were most sensitive to radiation damage during the G2-M
phase. Thus, the increased blockage caused by L-dopa during
treated with L-dopa
the G2-M phase may indicate increased cell damage and an
inability to proliferate or, alternatively, may merely reflect
oa (Gy -') (Gy-2) the accumulation of dead cells during the G2-M phase, and
0.175 ± 0.010 0.044 ± 0.010 hence the potentiation of radiation cell killing by the L-dopa.
The biochemical mechanism of radiosensitisation by L-
0.143 ± 0.007 0.026 ± 0.004 dopa remains to be studied. Wick et al. (1977) and Wick
(1978) have postulated that L-dopa acts on melanoma cells
0.209 ± 0.012 0.035 ± 0.005 through an initial conversion to quinones mediated by
tryosinase and a subsequent scavenging action on the
sulphydryl groups, by which DNA polymerase a may be
inactivated. This hypothesis is supported by the fact that
1,2-benzoquinones have a marked affinity for DNA
iave remarkably high survival polymerase a (Graham et al., 1978) and that L-dopa inhibits
'ing a course of fractionated the activity of DNA polymerase a only in the presence of
n, 30 fractions), when com- tyrosinase (Wick, 1980). Recently, Lonn and Lonn (1985)
ig a smaller shoulder. Thus, have demonstrated that DNA polymerase a is involved in the
kay be an effective means of repair process of DNA lesions induced by X-ray irradiation
n the radiation survival curve in human melanoma cells. Hence, it might be possible that
seen in melanomas. Our data indicated that non-melanoma
control cells were unaffected by the same L-dopa treatment.
This suggests that L-dopa may potentiate the radiation toxi-
city selectively in melanoma cells, and probably does not
affect normal tissue that has no tyrosinase. Thus, the
therapeutic ratio in the management of melanomas may be
enhanced by the use of L-dopa.
Our present data have also demonstrated that the PLD
repair of the HMV-I melanoma cells was significantly
inhibited by post-radiation incubation of the irradiated cells
with L-dopa. Recently, radiotherapy using large dose per
fraction has been proposed for the therapy of human
melanoma (Habermalz & Fischer, 1976; Overgaard, 1980),
aiming at overcoming the large shoulder in the melanoma
Table III Percentages of HMV-I human melanoma cells at G,, S
and G2-M phases of cell cycle measured 24 h after the completion of
treatments
Percentages
Treatments GI S G2-M
Control 59 ± 8 28 ± 6 15 ± 7
L-dopa (100 tLgml-') 58 ± 9 28 ± 8 14 ± 9
Radiation (10 Gy) 47 ± 5 25 ± 8 28 ± 2
Radiation + L-dopa 44 ± 7 18 ± 4 38 ± 3
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L-dopa inhibits the repair of radiation-induced DNA lesions
through inactivating DNA polymerase a, and thus poten-
tiates the radiation cytotoxicity in melanoma cells.
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